CRP and vasculitis: In 2014, 10 mg/Kg Infliximab was resumed until 2017, when it was stopped again in relation to the suspicion of secondary vasculitis due to the onset of low-grade recurrent fever, mild persistence in C-reactive protein (CRP) increase (up to 1.5 mg/dL), and mild transitory serum creatinine increase (up to 1.6 mg/dL).